Company: BSX
Filing Date: 2025-11-03
Form Type: 10-Q
Source: 0000885725-25-000050
Chunk: 47

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-11-03
Form: 10-Q
Item: Part I, Item 1
Chunk 47
---
 of Contents

(in millions)Bolt MedicalSoniVieOtherGoodwill$304 $248 $408 Amortizable intangible assets142 — 216 Indefinite-lived intangible assets376 344 — Other assets acquired28 12 91 Net deferred tax assets— — 11 Liabilities assumed(22)(23)(55)Net deferred tax liabilities(46)(65)(41)$782 $516 $631 Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies, none of which is deductible for tax purposes.We allocated a portion of the purchase price to the specific intangible asset categories as follows:Amount Assigned(in millions)Weighted Average Amortization Period(in years)Risk-Adjusted Discount Rates used in Purchase Price AllocationBolt Medical:Amortizable intangible assets:Technology-related$142 1215%Indefinite-lived intangible assets:In-process research and development (IPR&D)$376 N/A15%$518 SoniVie:Indefinite-lived intangible assets:IPR&D$344 N/A20%$344 Other:Amortizable intangible assets:Technology-related$202 1218%Customer relationships and other intangibles15 1218%$216 Our technology-related intangible assets consist of technical processes, intellectual property and institutional understanding with respect to products and processes that we intend to leverage in future products or processes. We used the multi-period excess earnings method, a form of the income approach, to derive the fair value of the technology-related intangible assets and are amortizing them on a straight-line basis over their assigned estimated useful lives.2024 AcquisitionsOn September 17, 2024, we completed our acquisition of 100 percent of the outstanding equity of Silk Road Medical, Inc. (Silk Road Medical), a publicly traded medical device company that has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR). The transaction consisted of an upfront cash payment of $27.50 per share, or approximately $1.126 billion, net of cash acquired. The Silk Road Medical business is being integrated into our Peripheral Interventions division.

11

Table of Contents

Purchase Price Allocation We accounted for this transaction as a business combination in accordance with Financial